StartATHA • NASDAQ
add
Athira Pharma Inc
Seneste lukkekurs
0,30 $
Dagsinterval
0,28 $ - 0,31 $
Årsinterval
0,22 $ - 3,67 $
Markedsværdi
11,25 mio. USD
Gns. volumen
237,93 t
P/E-værdi
-
Udbytteprocent
-
Primær børs
NASDAQ
Markedsnyheder
Økonomi
Resultatopgørelse
Indtægt
Nettoindtægt
| (USD) | dec. 2024info | År til år-ændring |
|---|---|---|
Indtægt | — | — |
Driftsudgifter | 15,57 mio. | -49,20 % |
Nettoindtægt | -15,00 mio. | 45,01 % |
Overskudsgrad | — | — |
Earnings per share | — | — |
EBITDA | -15,32 mio. | 49,59 % |
Effektiv afgiftssats | — | — |
Årsbalance
Samlede aktiver
Samlede passiver
| (USD) | dec. 2024info | År til år-ændring |
|---|---|---|
Kontanter og korttidsinvesteringer | 51,28 mio. | -65,22 % |
Samlede aktiver | 58,78 mio. | -63,32 % |
Samlede passiver | 13,94 mio. | -53,63 % |
Samlet egenkapital | 44,84 mio. | — |
Shares outstanding | 39,04 mio. | — |
Kurs/indre værdi | 0,26 | — |
Afkast af aktiver | -53,67 % | — |
Afkast af kapital | -74,16 % | — |
Pengestrøm
Nettoændring i likviditet
| (USD) | dec. 2024info | År til år-ændring |
|---|---|---|
Nettoindtægt | -15,00 mio. | 45,01 % |
Pengestrøm fra drift | -26,01 mio. | 1,06 % |
Pengestrøm fra investering | -2,81 mio. | -144,00 % |
Pengestrøm fra finansiering | 34,00 t | -77,63 % |
Nettoændring i likviditet | -28,79 mio. | -45,78 % |
Fri pengestrøm | -12,30 mio. | 32,48 % |
Om
Athira Pharma is a late clinical stage American biopharmaceutical company developing small molecules to restore neuronal health and stop the neurodegeneration brought on by diseases such as Alzheimer's disease and Parkinson's disease. The company's lead candidate, ATH-1017, is in human studies for Alzheimer's disease as of 2021.
The company was founded in 2011 and is headquartered in Seattle. Funding that supports the company is from both public and private investment groups including the Alzheimer's Drug Discovery Foundation, Dolby Family Ventures, the State of Washington's Life Sciences Discovery Fund, The W Fund, WRF Capital, and other private investors.
Leen Kawas served as the company's first President and CEO, but resigned in October 2021, after an independent special committee found she "altered images in scientific papers she authored." In 2025, the company paid a $4 million settlement in relation to allegations that the CEO falsified research to secure a federal grant. On October 21, 2021, Mark Litton, Ph.D., M.B.A. became chief executive officer. Wikipedia
Grundlagt
2011
Hovedkvarter
Website
Ansatte
26
